Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status
Open accessThe DOI matches its Crossref record; 88 of the 91 references it cites were found in a registry or an index.
Abstract
Viloxazine has a long history of clinical use in Europe as an antidepressant, and has recently been repurposed into an extended-release form for the treatment of attention-deficit/hyperactivity disorder in the USA. An immediate-release formulation was approved for the treatment of depression in the UK in 1974, and was subsequently marketed there and in several European countries for 30 years with no major safety concerns. In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic effects of viloxazine are thought to be primarily the result of its action as a norepinephrine reuptake inhibitor, although in vitro and preclinical in vivo animal data suggest that viloxazine may also impact the serotoninergic system. This review summarizes the evolving knowledge of viloxazine based on information from previously published preclinical and clinical investigations, and acquired unpublished historical study reports from both open-label and blinded controlled clinical trials. We review the chemical properties, mechanism of action, safety, and tolerability across these studies, and discuss the contemporary rationale for the development of this agent as an extended-release oral formulation for the treatment of attention-deficit/hyperactivity disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“has long been used in Europe to treat depression [74]”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Arzneimittelforschung: Eine Zukunftsoption für Ärzte?
Bethke, T. D. (2012) · Der Pneumologe · doi:10.1007/s10405-012-0601-3 · Cited by 3,261
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757 · cited 1×
“The minimal impact of viloxazine on dopamine in the nucleus accumbens, a region known for its key role in substance use disorders [20, 21], may be associated with a low abuse liability [22].”
BackgroundFoye's Principles of Medicinal Chemistry
Foye, W. O., Lemke, T., & Williams, D. A. (2012) · Cited by 1,407
Pharmacotherapy of Attention-Deficit Hyperactivity Disorder across the Life Cycle
SPENCER, T., BIEDERMAN, J., WILENS, T., HARDING, M., O'DONNELL, D., & GRIFFIN, S. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199604000-00008 · Cited by 830 · cited 1×
“In certain situations, stimulants can fail to provide satisfactory symptom control [79], and have a known potential for abuse [22].”
BackgroundFaraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631 · cited 1×
“Notably, dysregulated dopamine signaling in the prefrontal cortex and amygdala has been implicated in the pathophysiology of ADHD [23–28], and is a primary target of many effective ADHD medications [27, 29, 30].”
BackgroundDopamine in Drug Abuse and Addiction: Results of Imaging Studies and Treatment Implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., Swanson, J. M., & Telang, F. (2007) · Archives of Neurology · doi:10.1001/archneur.64.11.1575 · Cited by 605
Swanson, J. M., Kinsbourne, M., Nigg, J., Lanphear, B., Stefanatos, G. A., Volkow, N., Taylor, E., Casey, B. J., Castellanos, F. X., & Wadhwa, P. D. (2007) · Neuropsychology Review · doi:10.1007/s11065-007-9019-9 · Cited by 580
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.11.1652 · Cited by 528
Research works printed but not linked: 6
- Marsh W. Viloxazine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. Amsterdam: Elsevier Inc; 2007.
- National Center for Biotechnology Information, PubChem database. Viloxazine, CID = 5666. https://pubchem.ncbi.nlm.nih.gov/compound/Viloxazine. Accessed 17 Jan 2019.
- Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:122–5.
- Greenwood DT. Animal pharmacology of viloxazine (Vivalan). J Int Med Res. 1975;3:18–28.
- Turner P, Bayliss PFC, Ghose K. Clinical pharmacoolgy of viloxazine (Vivalan). J Int Med Res. 1975;3:41–7.
- Murphy JE. Vivalan: drug profile. J Int Med Res. 1975;3:112–5.
Cited by
Chirality of New Drug Approvals (2013–2022): Trends and Perspectives
McVicker, R. U., & O’Boyle, N. M. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02239 · Cited by 255
Becker, S. P., Willcutt, E. G., Leopold, D. R., Fredrick, J. W., Smith, Z. R., Jacobson, L. A., Burns, G. L., Mayes, S. D., Waschbusch, D. A., Froehlich, T. E., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2022.07.821 · Cited by 175
Nazarova, V. A., Sokolov, A. V., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1066988 · Cited by 111
Functional Impairments Associated With ADHD in Adulthood and the Impact of Pharmacological Treatment
Kosheleff, A. R., Mason, O., Jain, R., Koch, J., & Rubin, J. S. (2023) · Journal of Attention Disorders · doi:10.1177/10870547231158572 · Cited by 133
“Although the abuse liability of viloxazine extended-release has not been directly tested in humans, the original formulation of viloxazine has a 30+ year history of clinical use in Europe, with no indication of abuse potential (Findling et al., 2021).”
BackgroundDrug Repurposing of Generic Drugs: Challenges and the Potential Role for Government
van der Pol, K. H., Aljofan, M., Blin, O., Cornel, J. H., Rongen, G. A. P. J. M., Woestelandt, A.-G. B., & Spedding, M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00816-6 · Cited by 68
“An example of a successfully repurposed generic drug is viloxazine, a selective noradrenaline uptake inhibitor, which was originally approved and marketed for the treatment of depression in Europe but was never approved or marketed in the USA [41].”
Background
Metadata
- Authors
- Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H.
- Affiliations
- Virginia Commonwealth University (US)
- Supernus Pharmaceuticals (United States) (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Findling, Robert L.
- ORCID
- Venue
- CNS Drugs
- Published
- 2021-05-18
- Volume
- 35
- Issue
- 6
- Pages
- 643-653
- ISSN
- 1172-7047 (ISSN-L)
- 1179-1934
- PMC
- PMC8219567
- OpenAlex
- W3160925470
- Cited by
- 55
- References
- 91
- Citations by year
- 2026: 6 · 2025: 8 · 2024: 12 · 2023: 11 · 2022: 16 · 2021: 2
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- CNS Drugs (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Sunovion
- Supernus Pharmaceuticals
- National Institute of Child Health and Human Development
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- viloxazine, antidepressants, attention deficit hyperactivity disorder, drug repurposing, sustained-release formulation, norepinephrine reuptake inhibitors, serotonergic system, cardiotoxicity, gastrointestinal adverse effects, drug safety and tolerability, mechanism of action
- MeSH terms
- Administration, Oral, Animals, Attention Deficit Disorder with Hyperactivity, Central Nervous System Diseases, Delayed-Action Preparations, Humans, Viloxazine, Adrenergic Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. https://app.cochat.ai/papers/10.1007/s40263-021-00825-w
- The paper
- Findling, R. L., Candler, S. A., Nasser, A. F., Schwabe, S., Yu, C., Garcia-Olivares, J., O’Neal, W., & Newcorn, J. H. (2021). Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. https://doi.org/10.1007/s40263-021-00825-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
